Stockscreener 앱 받기
0.00
100.00%
-7.85
Synaptogenix Inc 주식(SNPX)의 최신 뉴스
Small-cap healthcare stocks with explosive potential - businessnewsthisweek.com
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
This cryptocurrency breaks into the elite of digital assets used as reserves in corporate treasuries. - Bit2Me News
TAO Is Next for Corporate Treasury, Nasdaq Giants Fuel Bittensor’s 10% Rally - Coinspeaker
Bittensor (TAO) Becomes the Next Pick in the Wave of Public Crypto Treasuries - BeInCrypto
Health Care Sector Sees Mixed Results And Strategic Moves - Finimize
Synaptogenix pumps $100m into artificial intelligence token - Mugglehead Magazine
Klotho Neurosciences Sees Massive Jump After Promising Gene Study - Finimize
Synaptogenix (SNPX) Unveils AI-Focused Cryptocurrency Strategy | SNPX Stock News - GuruFocus
Synaptogenix, Inc. announced that it expects to receive $5.5 million in funding - MarketScreener
Synaptogenix Unveils TAO-Focused Crypto Treasury Plan - Live Bitcoin News
Synaptogenix Appoints James Altucher to Lead Digital Asset Treasury Strategy - citybiz
Synaptogenix Says On June 8, Alan Tuchman Resigned As CEO And Director Of Co - MarketScreener
Synaptogenix Launch Of Differentiated Cryptocurrency Treasury Strategy Focused Exclusively On AI Crypto Token 'TAO' - marketscreener.com
Synaptogenix Stock Soars on Bold AI Crypto Bet - RagingBull
Synaptogenix Announces $5.5M Securities Purchase Agreement - TipRanks
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasu - GuruFocus
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token | SNPX Stock News - GuruFocus
First Pure-Play AI Crypto Stock: Synaptogenix Commits $100M to Leading AI Token TAO, Appoints Crypto Expert - Stock Titan
Full Stock Market News from 2025-06-06 - Stock Titan
Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update - Defense World
Synaptogenix (NASDAQ:SNPX) Trading 1.5% Higher – Here’s What Happened - Defense World
Full Stock Market News from 2025-05-27 - Stock Titan
Full Stock Market News from 2025-05-22 - Stock Titan
SNPXSynaptogenix Latest Stock News & Market Updates - Stock Titan
Geode Capital Management LLC Takes $39,000 Position in Synaptogenix, Inc. (NASDAQ:SNPX) - Defense World
Synaptogenix stock plunges to 52-week low of $2.14 By Investing.com - Investing.com Canada
Synaptogenix stock plunges to 52-week low of $2.14 - Investing.com Australia
Synaptogenix Inc. (SNPX) reports earnings - qz.com
Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews
Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Informatica Leads Gartner Magic Quadrant for Data Integration Tools for 19th Straight Year - Stock Titan
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
0.39%
0.42%
자본화:
|
볼륨(24시간):